论文部分内容阅读
目的 :探索增生细胞核抗原 PCNA与良性脑膜瘤复发的关系。方法 :使用 S- P免疫组化的方法检测脑膜瘤复发组与对照组 PCNA的表达。结果 :复发组第 1次手术切除标本的 PCNA L I为 (14 .0 3± 12 .72 ) % ,对照组为 (0 .82± 0 .6 5 ) % (P<0 .0 1)。复发组 PCNA L I均 >2 .0 % ,对照组 PC-NA L I均 <2 .0 %。复发组同一患者前后两次手术切除标本的 PCNA L I无显著性差异。复发组与对照组间年龄、性别均无显著性差异 (P>0 .0 5 )。结论 :PCNA L I对判断全切除的良性脑膜瘤复发有较高的预测价值。当脑膜瘤的 PCNA L I>2 .0 %时 ,提示有复发风险。患者的年龄、性别、组织学类型与肿瘤复发无关。
Objective: To explore the relationship between proliferating cell nuclear antigen PCNA and recurrent benign meningioma. Methods: The expression of PCNA in meningioma recurrence group and control group was detected by S-P immunohistochemistry. Results: The PCNA L I in the first surgical resection group was (14 .0 3 ± 12 .72)% and that in the control group was (0.82 ± 0.056)% (P <0.01). The recurrence group PCNA L I were> 2.0%, the control group PC-NA L I were <2.0%. There was no significant difference in PCNA L I between the two groups before and after resection in the same patient. There were no significant differences in age and sex between the recurrence group and the control group (P> 0.05). CONCLUSION: PCNA L I has high predictive value for judging the recurrence of benign meningioma. When meningioma PCNA L I> 2.0%, suggesting a risk of recurrence. The patient’s age, sex, histological type have nothing to do with tumor recurrence.